Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Clinical trial NCT07181109 · RECRUITING

Trial details

NCT number: NCT07181109
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

High Risk Cardiovascular Disease Hypertension High Cardiovascular Risk

Start date: 2025-09-22
Primary completion: 2030-09-30
Enrollment: 11000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.